Janice Mehnert, Associate Director For Clinical Research at
“First paper of 2024! In a retrospective analysis, adjuvant therapy appears to benefit patients with acral, but not mucosal, melanoma. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based th…”
Source: Janice Mehnert/X